Pardes Bioscience Announces Issuance of Its First U.S. Patent CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new...

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the...

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat...